For the year ending 2025-12-31, OBIO had $12,429K increase in cash & cash equivalents over the period. -$49,452K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Total revenue-Partnership Revenue | 32,871 |
| Total revenue-Product | 611 |
| Cost of product revenues | 190 |
| Development costs-Non Clinical Development Costs | 17,979 |
| Development costs-Clinical Development Costs | 12,945 |
| Personnel and consulting costs | 30,028 |
| Stock-based compensation | 11,978 |
| Depreciation and amortization expense | 327 |
| Other segment expenses | 11,588 |
| Interest expense (income), net | -1,148 |
| Net loss | -52,701 |
| Depreciation and amortization | 327 |
| Stock-based compensation | 11,978 |
| Non-cash interest expense on liability related to the royalty purchase agreement | 2,048 |
| Accretion and interest related to marketable securities | 811 |
| Non-cash lease expense | 607 |
| Change in the fair value of derivative liability | 254 |
| Amortization of deferred financing fees | 215 |
| Accounts receivable | 3 |
| Inventory | 137 |
| Prepaid expenses and other assets | -880 |
| Accounts payable, accrued expenses and other liabilities | 4,866 |
| Operating lease liabilities - current and non-current | -550 |
| Deferred revenue | -15,428 |
| Net cash used in operating activities | -48,963 |
| Purchases of property and equipment | 489 |
| Sales of marketable securities | 49,860 |
| Purchases of marketable securities | 76,312 |
| Net cash (used in) provided by investing activities | -26,941 |
| Proceeds from sale of common stock and pre-funded warrants, net of issuance costs | 57,780 |
| Proceeds from the royalty purchase agreement | 20,000 |
| Proceeds from issuance of series a preferred stock | 12,557 |
| Repayment of royalty liability | 972 |
| Proceeds from at-the-market offering, net of issuance costs | 1,543 |
| Proceeds from exercise of stock options | 91 |
| Restricted stock units withheld for tax | 1,552 |
| Deferred financing costs | 1,114 |
| Net cash provided by financing activities | 88,333 |
| Net increase (decrease) in cash and cash equivalents | 12,429 |
| Cash and cash equivalents, beginning of the period | 22,261 |
| Cash and cash equivalents, end of the period | 34,690 |
Orchestra BioMed Holdings, Inc. (OBIO)
Orchestra BioMed Holdings, Inc. (OBIO)